	1		
_		-	

	Please type a	plus sign	(+) inside	this box →						Patent an	Ap d Trader	proved for use through 10/31/99. OMB nark Office: U.S. DEPARTMENT OF CO	0651-0031 OMMERCE
	Under the Pap	erwork A	eduction A	act of 1995,	no persor	ns are required to res	spond to a collection	of information unles	s it con	itains a valid OMB	control n	umber	
				om 1449								if Known	
/	PE			TEME	NT E	DISCLOS BY APPLIC ets as necessa	CANT	Application N	lumb	er		09/978,333	
/d	) .	-aggr	图"	ise as me	y 3.10	013 43 11000004	• * * * * * * * * * * * * * * * * * * *	Filing Date				October 15, 2001	
l I	0 %	•	8					First Named	nven	itor		Peter M. Glazer	
١.	N/G .		₹					Group Art Un	it			1655	
N	•		<b>*/</b>					Examiner Na	ne				
	SNOTFAT	RIP I	f	of	I	7		Attorney Doc	ket N	lumber		YU 132 (OCR 653)	
	SALI				<u> </u>								
				_			U.S. PATE	NT DOCUMEN	ιτs				
	Examiner Initials*	Cite No. <sup>1</sup>	US Pa	Atent Docu	ment		of Patentee or Ap of Cited Documen			Document M-DD-YYYY		ages, Columns, Lines, Where Rele Passages or Relevant Figures App	
					known)								
	741		5,962,4	26		Glazer			10-0	5-1999			
			5,422,2	251		Fresco			06-0	6-1995			
	)												
			<u></u>										
					—							<del>{E(;E V = )</del>	
					├								
:			<b></b>		-							AUG 0 9 2002	
			-,		<del> </del>							MUG U 3 ZUUZ	
							·		_			<del>-</del>	
			· · · · · ·								TE	AL AERITED IRANIDAN	1
											15	OU OFIAIRU IOAAIRAA	•
							FOREIGN D	TENT BOOK	CACT				
		0:14	r	C:	Datast	Document		ATENT DOCUM of Patentee or	IENI	Date of Publical	ion of	Pages, Columns, Lines, Where	1 78
	Examiner Initials*	Cite No. <sup>1</sup>	Office.3		umber*	Kind Cod	Applicant e <sup>5</sup>	of Cited Docume	nt	Cited Documen DD-YYYY	t MM-	Relevant Passages or Relevant Figures Appear	
						(if known)							
	Ch		wo	95/0136	4		Yale Unive	sity		01/12/1995	$\longrightarrow$		
			L										
										L			
							_						
	<b></b>		<del> </del> -				_			· · · · · · · · · · · · · · · · · · ·	$\dashv$		
			L	l						L			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Examine

Signature

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →	+

PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

YU 132 (OCR 653)

9-20-0

Substitute for form 1449A/PTO		Complete if Known		
INFORMATION DISCLOSURE E STATEMENT BY APPLICANT  Less as many sheets as necessary)	Application Number	09/978,333	ECH CEN	AUG
50 6	Filing Date	October 15, 2001	П	0
<u>⊘ ≨</u>	First Named Inventor	Peter M. Glazer	20	9
' <b>\$</b> /	Group Art Unit	1655	6	2

Examiner Name

Attorney Docket Number

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiners	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T
Initials*	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	
		publisher, city and/or country where published	
		BAUMANN, et al., "Role of the human RAD51 protein in homologous recombination and double-stranded-break repair," Trends	
_		Biochem Sci 23(7):247-251 (1998).	
	İ	Diothem 3ct 25(7).247-251 (1976).	
<u> </u>			
1 (	l	BEAL, et al., "Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation," Science 251:1360-	
1 1		1363 (1991).	
		BEAL, et al., "The influence of single base triplet changes on the stability of Pur-Pur-Pyr triple helix determined by affinity cleaving,"	
1 1	1	Nuc. Acids Res. 20(11):2773-2776 (1992).	
1 1	İ	Trac. Actus Nes. 20(11).2175-2170 (1792).	
ļ			
1 1 1		BLUME, et al., "Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter,"	
		Nucleic Acids Res. 20:1777-1784 (1992).	
1 1 1			
		BRENNEMAN, et al., "Stimulation of intrachromosomal homologous recombination in human cells by electroporation with site-specific	
1 1 1		endonucleases," Proc. Nail. Acad. Sci. USA 93(8): 3608-12 (1996).	
1 1 1		Control   Cont	
<del> </del>		CAMPORIA	
1 1		CAMPBELL, et al., "Homologous recombination involving small single-stranded oligonucleotides in human cells," New Biol. 1(2):223-	
		7 (1989).	
L			
		CAPECCHI, "Altering the genome by homologous recombination," Science 244(4910): 1288-1292 (1989).	
1 1 1			
1 1 1			
<del> </del>		CHAN, et al., "Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming	_
1 1			
!!!		oligonucleotide," J. Biol. Chem. 274(17): 11541-11548 (1999).	
1 1		COONEY, et al., "Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro," Science 241: 456-459	- 1
1 11		(1988).	
		DURLAND, et al., "Binding of triple helix forming oligonucleotides to sites in gene promoters," Biochemistry 30:9246-9255 (1991).	_
		1 Series and Series and Series and Series and Series and Series and Series promoters, Districtions of Series and Series a	
l , l			
		<u></u>	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner's

Signature

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO	Complete If Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  Output  Discrete as many sheets as necessary)	Application Number	09/978,333		
the as many sheets as necessary)	Filing Date	October 15, 2001		
6,2 P	First Named Inventor	Peter M. Glazer		
The as many sheets as necessary)	Group Art Unit	1655		
	Examiner Name			
SNOW TEAM & TRUS Of 7	Attorney Docket Number	YU 132 (OCR 653)		

•		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
CM		DUVAL-VALENTIN, et al., "Specific inhibition of transcription by triple helix-forming oligonucleotides," Proc. Natl. Acad. Sci. USA 89:504-508 (1992).	
		FARUQI, et al., "Triple-helix formation induces recombination in mammalian cells via a nucleotide excision repair-dependent malbyway," Mol Cell Biol 20(3): 990-1000 (2000).	
		FELSENFELD, et al., "Formation of a three-stranded polynucleotide molecule," J. Am. Chem. Soc. 79:2023-2024 (1957).	AUG
		FRANCOIS, et al., "Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline-copper chelate," <i>Proc. Natl. Acad. Sci. USA</i> 86:9702-9706 (1989).	0 9 2
		GLAZER, et al., "DNA mismatch repair detected in human cell extracts," Mol. Cell. Biol. 7:218-224 (1987).	2002
,		GONCZ, et al., "Site-directed alteration of genomic DNA by small-fragment homologous replacement," Methods Mol. Biol. 133:8 (2000).	
		GRIGORIEV, et al., "A triple helix-forming oligonucleotide-intercalator conjugate acts as a transcriptional repressor via inhibition of NF kappa B binding to interleukin-2 receptor alpha-regulatory sequence," J. of Biological Chem. 267:3389-3395 (1992).	
		HANSON, et al., "Analysis of biological selections for high-efficiency gene targeting," Mol. Cell. Biol. 15(1):45-51 (1995).	
		HAVRE, et al., "Targeted mutagenesis of simian virus 40 DNA mediated by a triple helix-forming oligonucleotide," <i>J. Virology</i> 67:7324-7331 (1993).	
		HELENE, "Sequence-selective recognition and cleavage of double-helical DNA," Curr. Opinion Biotechnology 4:29-36 (1993).	

Examiners Signature	Courses	Date Considered	9-20-24
*EXAMINER:	Initial if reference considered, whether of not citation is in conformance with MPEP 60	9. Draw line thro	ugh citation if not in conformance and not considered.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Translation is attached

Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language

Substitute for form 1449A/PTO	Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  PE C as many sheets as necessary)	Application Number	09/978,333		
as many sheets as necessary)	Filing Date	October 15, 2001		
O STORE THE STORE OF THE STORE	First Named Inventor	Peter M. Glazer		
(16) Della (16)	Group Art Unit	1655		
AND SEE	Examiner Name			
of 7	Attorney Docket Number	YU 132 (OCR 653)		

		OTHER ART NON PATENT LITERATURE DOCUMENTS
E	L 0'1-	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the
Examiners	Cite	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).
Initials*	No.1	ntem (book, magazine, journar, senar, symposium, catalog, etc.), date, pagees, volumenssae number(s).  publisher, city and/or country where published
	ļ	
ŀ	ŀ	ITO, et al., "Sequence-specific DNA purification by triplex affinity capture," Proc. Natl. Acad. Sci. USA 89:495-498 (1992).
	l	<b>'</b>
( M	ļ	
		JAKUBCZAK, et al., "Analysis of genetic instability during mammary turnor progression using a novel selection-based assay for in vivo
(	ŀ	mutations in a bacteriophage lambda transgene target," Proc. Natl. Acad. Sci. USA 93:9073-9078 (1996).
	<del>                                     </del>	JONES, et al., "Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA." Biochemistry
	}	32:12096-12104 (1993).
		52.12090-12104 (1993).
<del> </del>	-	LETAl, et al., "Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide
	l	
		affinity columns," Biochemistry 27:9108-9112 (1988).
<b> </b>	<b>—</b>	LIN, et al., "Extrachromosomal recombination in mammalian cells as studied with single- and double-stranded DNA substrates," Mol.
1 1		
1 1		Cell Biol 7(1):129-140 (1987).
<b></b>		LIN, et al., "Use of EDTA derivatization to characterize interactions between oligodeoxyribonucleoside methanicosphonates and nu cleic
1 1		Lin, et al., "Use of EDTA derivatization to characterize interactions between offigure oxymboliacteoside metractions and to-to-
1 1		acids," Biochemistry 28:1054-1061 (1989).
l l	į .	2 9 10
		LUO, et al., "High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides and oinjected into moise
1 1	1	cells," Proc. Natl. Acad. Sci. USA 97(16): 9003-9008 (2000).
	1	5 0 III L
	$\vdash$	MAHER, et al., "Analysis of promoter-specific repression by triple-helical DNA complexes in a eukaryotic cell-the transcription"
l i	1	system," Biochemistry 31:70-81 (1992).
	1	system, blockermany 31.170 tr (1772).
<del>  -</del>	├	MAHER, et al., "Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation," Science 23:725-130 (1939)
1 1		WATER, et al., minimum of Divi omaning process by ongoing contacted affected
1 1	1	
<u> </u>	ļ	
1 1	l	MERGNY, et al., "Sequence specificity in triple-helix formation: experimental and theoretical studies of the effect of mismatches on
1 1/	1	triplex stability," Biochemistry 30:9791-9798 (1991).
	1	

Examiners	( ) h	Date Considered	
Signature	1 ('Kelx S	1 9.00.09	
-	1 7, - 7, -		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant to place a check mark here if English language Translation is attached.

Ple	ease type a	a plus sign	ı (+) insidi	e this box →	·			Approved for Patent and Trademark Office:	PTO/SB/08A (10- use through 10/31/99. OMB 0651-00; U.S. DEPARTMENT OF COMMERC	131
Un	ider the Pa	aperwork F	Reduction	Act of 1995,	no persons	are required to respond t	to a collection of information unless it con	tains a valid OMB control number		
		Substit	ute for	form 1449	A/PTO			Complete if Known	AUG H CEN	
	PE	_SJ	ATE	MENT	BY A	CLOSURE PPLICANT necessary)	Application Number	09/978,333	0 9 2002 VIER 1600/	
/b	)	M	لين	aoa, .		,,	Filing Date	October 1	5, 2001	_
	_	2 Dire	割				First Named Inventor	Peter M. G		-
	211	, -	5				Group Art Unit	1655	8	-
V	Ma		\$				Examiner Name			-
7	ALL.	T .	<del>?}/</del>	of	1	7	Attorney Docket Number	YU 132 (O	CB 663)	-
5	EM	TRAN		L	<del></del>	<del>'</del>	Attorney Booket Hamber	1.0.102.(0.	311 0007	-
							NON PATENT LITERATURE (			_
	xaminer Initials*	s Cite No.	MOSE	R, et al., "	item (bo	ok, magazine, journa	(in CAPITAL LETTERS), title of the il, serial, symposium, catalog, etc.), publisher, city and/or country where double helical DNA by triple he	date, page(s), volume-issue num e published	nber(s)	
		·	18:308	3-315(1991	i).		a transgenic mouse model for de		~	_
			Natl. A	Icad. Sci. V	USA 94:31	22-3127 (1997).	·		-	
			lymph	ocytes," N	ucleic Acid	ds Res. 19:3435-344			<u> </u>	_
	+		Sci. U.	SA 91:5013	7-5021 (19	994).	by human XPA, ERCCI, and ER		`	
	+	!				and distal effects of ol. 236:491-502 (19	sequence context on ultraviolet n 94).	nutational hotspots in a shuttle v	rector replicated in	
				<i>al.</i> , "Site- i8-9862 (1		eavage of duplex D	NA by a semisynthetic nuclease v	ria triple-helix formation," <i>Proc</i>	. Nail. Acad. Sci. USA	_
				OUALT, e 8-360 (19		uence-specific artifi	cial photo-induced ndonucleases	based on triple helix-forming of	igonucleotides," Nature	
							ng oligodeoxyribonucleotide bind SA 88:8227-8231 (1991).	ls to the c-myc promoter in HeL	a cells, thereby reducing	

		$\sim$			
Examiner's	/	$\mathcal{T}$	V 0 4 O	Date Considered	0 20 00
Signature	{		Maria		9-00-04
			· · · · · · · · · · · · · · · · · · ·		

POSVIC, et al., "Sequence-Specific Alkylation of Double-Helix DNA by Oligonucleotide-Directed Triple-Helix Formation," J. Am. Chem Soc. 112:9428-9430 (1990).

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →	+	

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+	

Substitute for form 1449A/PTO	Co	mplete if Known	0 元 元	A	开
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/978,333	ENTER 16	UG 0 9 2	<b>41.</b>
as many sheets as necessary)	Filing Date	October 15, 2001	8	00	T
02 B	First Named Inventor	Peter M. Glazer	2	10	
	Group Art Unit	1655	8		V
	Examiner Name		0		
Sheet FAT & TOP of 7	Attorney Docket Number	YU 132 (OCR 653)			

		OTHER ART NON PATENT LITERATURE DOCUMENTS
Examiner's Initials"	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
CH		PRASEUTH, et al., "Sequence-specific binding and photocrosslinking of alpha and beta oligodeoxynucleotides to the major groove of DNA via triple-helix formation," Proc. Natl. Acad. Sci. USA 85:1349-1353 (1988).
		REARDON, et al., "Removal of psoralen monoadducts and crosslinks by human cell free extracts," Nucleic Acids Res. 19:4623-4629 (1991).
		SAMBROOK, et al., MOLECULAR CLONING: A LABORATORY MANUAL, second edition, Cold Spring Harbor Laboratory Press, New York (1990).
		SANCAR, "DNA excision repair," Annu. Rev. Biochem. 65:43-81 (1996).
	•	SHIVJI, et al., "Proliferating cell nuclear antigen is required for DNA excision repair," Cell 69: 367-374 (1992).
		SIBGHAT-ULLAH, et al., "Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract," Nucleic Acids Res. 17:4471-4484 (1989).
		STROBEL, et al., "Site-specific cleavage of human chromosome 4 mediated by triple-helix formation," Science 254:1639-1642 (1991).
		SUNG, et al., "Recombination factors of Saccharomyces cerevisiae," Mutat Res 451:257-75 (2000).
		TAKASUGI, et al., "Sequence-specific photo-induced cross-linking of the two strands of double-helical DNA by a psoralen covalently linked to a triple helix-forming oligonucleotide," Proc. Natl. Acad. Sci. USA 88:5602-5606 (1991).
CM		THACKER, "A surfeit of RAD51-like genes?," Trends Genet 15(5):166-8 (1999).

	^		
Examiners	1) Nino.	Date Considered	0 2 77/
Signature			7-20-09

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant to place a check mark here if English language

Flease type a plus sign (+) inside this box →	T+

PTC/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b></b>	Patent and Tradental Conica. C.S. DEPATTMENT OF CON					
Under the Paperwork Reduction Act of 1995, no persons are required to respond to Substitute for form 1449A/PTO	1		당인	— A	PE	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (See as many sheets as necessary)	Application Number	09/978,333	ENTER 16	ψG 0 9 2!	CEN	
البير المكام	ATION DISCLOSURE IENT BY APPLICANT  Application Number  Ogyp78,333					
NIE O S TOTAL SEE	First Named Inventor	Peter M. Glazer	2	-		
Mp 72	Group Art Unit	1655	8		Ψ	
	Examiner Name		0		7	
Short and of 7	Attorney Docket Number	YU 132 (OCR 653)				

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
Cry		VASQUEZ, et al., "Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells," Nucleic Acids Res. 27:1176-1181 (1999).	
		WANG, et al., "Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair," Science 271: 802-805 (1996).	•
		WANG, et al., "Targeted mulagenesis in mammalian cells mediated by intracellular triple helix formation," Mol. Cell. Biol. 15:1759-1768 (1995).	
		WOOD, et al., "Complementation of the xeroderma pigmentosum DNA repair defect in cell-free extracts," Cell 53:97-106 (1988).	
Ö	-	YOUNG, et al., "Triple helix formation inhibits transcription elongation in vitro," Proc. Natl. Acad. Sci. USA 88:10023-10026 (1991).	
			·

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP.609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**Examiner's** 

Signature

9-20-04

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.